title: Significant association between expression of the CD11b surface molecule and favorable outcome for patients with acute myeloblastic leukemia.
abstract: The expression of several myeloid and non-lineage associated surface antigens in 70 patients with acute myeloblastic leukemia was investigated in relation to patient and disease characteristics, response to therapy, and prognosis. A leukocyte integrin, CD11b, was the only antigen that showed a significant association with complete remission (CR) duration and survival (P < .025). The mean survival for CD11b+ patients was longer than for CD11b- patients (578 +/- 76 versus 397 +/- 7 days, respectively). CR duration was 897 +/- 84 for CD11b+ patients and 366 +/- 71 for CD11b- patients. Multivariate analysis confirmed the predictive value of CD11b expression for longer survival (relative risk, 3.2; P = .02) and CR duration (relative risk, 3.2; P = .03). CR rate was also significantly higher in CD11b+ patients (77.3%) than in CD11b- patients (46.1%) (P = .01). Survival and remission duration were not influenced by expression of other surface markers including CD13, CD14, CD33, CD34, CD71, CD38, and HLA-DR or by other variables including French-American-British subtype, age, and leukocyte count. Extramedullary disease (EXD) was associated with the presence of both CD13 and CD14 expression (P < .04) but occurred less frequently in CD13+ cases. CD13 expression occurred more frequently in female patients (P = .03). CD38 expression was associated with lower platelet count and an increase in the number of blasts (P < .02).
authors.affiliation: Departments of Immunology, Shiraz University of Medical Sciences, Shiraz. amirzah@yahoo.com.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Amirghofran
authors.affiliation: Internal Medicine, Shiraz University of Medical Sciences, Shiraz.
authors.forename: Maryam
authors.initials: M
authors.lastname: Zakerinia
authors.affiliation: Fasa School of Medicine, Shiraz, Iran.
authors.forename: Azra
authors.initials: A
authors.lastname: Shamseddin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D016177:Macrophage-1 Antigen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016177:Macrophage-1 Antigen